Q1 2023 13F Holders as of 3/31/2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
138M
-
Number of holders
-
252
-
Total shares
-
72.9M
-
Shares change
-
-159K
-
Total reported value, excl. options
-
$1.85B
-
Value change
-
-$22.2M
-
Put/Call ratio
-
0.89
-
Number of buys
-
113
-
Number of sells
-
-139
-
Price
-
$25.40
Significant Holders of ARROWHEAD PHARMACEUTICALS, INC. - Common Stock (ARWR) as of Q1 2023
262 filings reported holding ARWR - ARROWHEAD PHARMACEUTICALS, INC. - Common Stock as of Q1 2023.
ARROWHEAD PHARMACEUTICALS, INC. - Common Stock (ARWR) has 252 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 72.9M shares
of 138M outstanding shares and own 52.94% of the company stock.
Largest 10 shareholders include BlackRock Inc. (12.7M shares), VANGUARD GROUP INC (10.7M shares), STATE STREET CORP (5.9M shares), JPMORGAN CHASE & CO (2.91M shares), Invesco Ltd. (2.18M shares), GEODE CAPITAL MANAGEMENT, LLC (2.08M shares), Avidity Partners Management LP (1.74M shares), Rokos Capital Management LLP (1.68M shares), CREDIT SUISSE AG/ (1.39M shares), and FMR LLC (1.37M shares).
This table shows the top 252 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.